Strategic Initiative

Slingshot members are tracking this corporate initiative:

Novartis (NVS) Agrees to Exclusive Worldwide License Agreement for Contaus Pharma's (CNAT) Orally Active Pan-Caspase Inhibitor Emricasan

Source Link:
http://ir.conatuspharma.com/releasedetail.cfm?ReleaseID=1004900

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
NVS
100%
CNAT
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!
Slingshot Insights Explained
JOIN FOR FREE TODAY
Strategic Initiative Date
Announcement Date:
Dec 19, 2016
Projected Implementation:
Q1, 2017
Relevance Tracked Until:
Q1, 2019
Related Projects Image

  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Exclusive Worldwide License Agreement, Orally Active, Pan-caspase Inhibitor, Emricasan
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.